InnovationRx: Positive Clinical Trial Results For Generative AI-Designed Drug
Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
marketinference13h
Gyre Therapeutics CEO expects pivotal phase 3 trial results in 2025
Financially, Gyre had cash and cash equivalents totaling $15.9 million as of September 30, 2024. For the third quarter of ...
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...
Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over 15 Companies are Progressing Through to Improve the Treatment Landscape | DelveInsight
The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
Gyre Therapeutics, Inc.: Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...
Aileron Therapeutics Reports Positive Phase 1b Data Of LTI-03 In Idiopathic Pulmonary Fibrosis
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
Yahoo Finance23h
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both ...